Announcement from Össur hf.No:28/2012
Reykjavik, 8 October 2012
Clinical results demonstrate that the Unloader One® reduces pain, increases function and life quality for knee osteoarthritis patients
Clinical study performed by Steadman Philippon Research Institute in the US demonstrates positive results on the function of Össur's osteoarthritis knee brace Unloader One®. The results demonstrate reduced pain and increased function. After six months 25% of patients reported reduction in usage of pain medication and 35% reported less usage of anti-inflammatories. These results in addition to other studies that have been performed on the function of Unloader One, in the past years, confirm Unloader One as an alternative treatment option for patients with osteoarthritis.
"Osteoarthitis is a major global health burden and the success of the Unloader One as a treatment for knee osteoarthritis has inspired us to focus on further innovation in non-operative treatment of osteoarthritis" said Jon Sigurdsson, president and CEO.
Steadman Philippon Research Institute is recognized globally for its pioneering research in osteoarthritis, surgery, and injury prevention and rehabilitation.
STUDY:
Briggs KK, Matheny LM, Steadman JR. Improvement in quality of life with use of an Unloader knee brace in active patients with OA: A prospective cohort study. J Knee Surg 2012; Advance online publication. Retrieved 23rd August 2012.doi:10.1055/s-0032-1313748
Össur press releases by e-mail
If you wish to receive Össur press releases by e-mail please register at the following web-site: http://www.ossur.com/investormailings (http://www.ossur.com/investormailings).
About Össur
Össur (NASDAQ OMX: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports, prosthetic limbs and compression therapy, including the Flex-Foot Cheetah carbon fiber running prostheses used by "The Blade Runner," renowned double-amputee sprinter Oscar Pistorius. A recognized "Technology Pioneer", Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com (http://www.ossur.com)
Forward-Looking Statements
This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Ossur Hf via Thomson Reuters ONE
